

Journal of Herpetological Medicine and Surgery

Performance of Three Portable Blood Glucose Meters in Inland Bearded Dragons (*Pogona vitticeps*)

--Manuscript Draft--

Manuscript Number:	JHMS-D-24-00024R1
Article Type:	Original Research
Keywords:	Glucose, glucometer, hyperglycemia, neuroendocrine, <i>Pogona vitticeps</i>
Corresponding Author:	Danielle K Tarbert, DVM, DACZM UTIA: The University of Tennessee Knoxville Institute of Agriculture Knoxville, TN UNITED STATES
First Author:	Danielle K Tarbert, DVM, DACZM
Order of Authors:	Danielle K Tarbert, DVM, DACZM Lisa Pacumio, BS Mélanie Ammersbach, DVM, DACVP Hugues Beaufrère, DVM, PhD
Abstract:	<p>Blood glucose concentration measurement is essential for the diagnosis and management of many bearded dragon (<i>Pogona vitticeps</i>) diseases. Portable blood glucose monitors (PBGMs) are inexpensive alternatives to traditional benchtop analyzers and require whole blood volumes as small as 0.3µL. However, PBGMs should be assessed for analytical and clinical agreement with a reference analyzer prior to use in a new species. The potential effects of variables such as packed cell volume (PCV) should also be evaluated. Using blood samples from 48 bearded dragons, three PBGMs were assessed, including a veterinary PBGM (VPBGM) using the canine and feline settings, a human PBGM (HPBGM), and a human point-of-care analyzer (LDX). Statistical analysis was performed using difference plots and Passing-Bablok regression analysis. Analytical agreement was determined using the bearded dragon-specific inherent imprecision of each analyzer, and clinical agreement was based on mammalian total allowable error (TEa) guidelines. A multiple linear regression model was used to investigate the potential effects of PCV, glucose, total solids (TS), lipemia, and hemolysis. The VPBGM overestimated blood glucose on both settings, while the HPBGM and LDX underestimated blood glucose. These respective discrepancies became more pronounced at higher blood glucose concentrations due to proportional biases. No analyzers had analytical agreement with the reference analyzer, and only the LDX was within acceptable clinical decision limits. However, if correction formulas were applied, all analyzers were in clinical agreement. A higher PCV was overall associated with an increasingly negative constant bias. There was no effect of TS concentration or lipemia. While the VPBGM and HPBGM are inexpensive analyzers compared to the LDX and reference analyzer, additional steps, such as the application of corrective formulas, are necessary to ensure acceptable diagnostic results. Alternatively, as precision was good for all analyzers and correlation to the reference analyzer was strong, method-specific reference intervals could be generated.</p>

1 **Performance of Three Portable Blood Glucose Meters in Inland Bearded Dragons (*Pogona vitticeps*)**

2

3 Danielle K Tarbert^{1,2*}, Lisa Pacumio¹, Mélanie Ammersbach³, Hugues Beaufrère¹

4

5 ¹Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California,

6 Davis, CA, 95616, USA

7 ²Present address (Tarbert): Department of Small Animal Clinical Sciences, College of Veterinary

8 Medicine, University of Tennessee, Knoxville, TN, 37996, USA

9 ³Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of

10 California, Davis, CA, 95616, USA

11

12 *Corresponding author: dtarbert@utk.edu

13

14 **Abstract**

15 Blood glucose concentration measurement is essential for the diagnosis and management of many

16 bearded dragon (*Pogona vitticeps*) diseases. Portable blood glucose monitors (PBGMs) are inexpensive

17 alternatives to traditional benchtop analyzers and require whole blood volumes as small as 0.3 μ L.

18 However, PBGMs should be assessed for analytical and clinical agreement with a reference analyzer

19 prior to use in a new species. The potential effects of variables such as packed cell volume (PCV) should

20 also be evaluated. Using blood samples from 48 bearded dragons, three PBGMs were assessed,

21 including a veterinary PBGM (VPBGM) using the canine and feline settings, a human PBGM (HPBGM),

22 and a human point-of-care analyzer (LDX). Statistical analysis was performed using difference plots and

23 Passing-Bablok regression analysis. Analytical agreement was determined using the bearded dragon-

24 specific inherent imprecision of each analyzer, and clinical agreement was based on mammalian total

25 allowable error (TE_a) guidelines. A multiple linear regression model was used to investigate the potential
26 effects of PCV, glucose, total solids (TS), lipemia, and hemolysis. The VPBGM overestimated blood
27 glucose on both settings, while the HPBGM and LDX underestimated blood glucose. These respective
28 discrepancies became more pronounced at higher blood glucose concentrations due to proportional
29 biases. No analyzers had analytical agreement with the reference analyzer, and only the LDX was within
30 acceptable clinical decision limits. However, if correction formulas were applied, all analyzers were in
31 clinical agreement. A higher PCV was overall associated with an increasingly negative constant bias.
32 There was no effect of TS concentration or lipemia. While the VPBGM and HPBGM are inexpensive
33 analyzers compared to the LDX and reference analyzer, additional steps, such as the application of
34 corrective formulas, are necessary to ensure acceptable diagnostic results. Alternatively, as precision
35 was good for all analyzers and correlation to the reference analyzer was strong, method-specific
36 reference intervals could be generated.

37

38

39 **Key Words:** Glucose, glucometer, hyperglycemia, neuroendocrine, *Pogona vitticeps*

40

41 **Introduction**

42 Blood glucose concentration measurement is essential for the diagnosis of multiple well-
43 described inland bearded dragon (*Pogona vitticeps*) diseases. Hyperglycemia is nearly always present in
44 highly malignant gastric neuroendocrine carcinomas (Ritter *et al.*, 2009; Anderson *et al.*, 2019) and has
45 been documented in other neoplasms such as lymphoid leukemia and hepatocellular carcinoma in this
46 species (Raiti, 2019; Hepps Keeney *et al.*, 2021). In reptile species in general, hyperglycemia may be
47 found in association with conditions such as stress, pancreatitis, and diabetes mellitus (Frye, 1991; Raiti,
48 2019). Recognition of hypoglycemia in reptiles is of equal importance, as this could indicate hepatic

49 failure or sepsis (Raiti, 2019). While many reptile species have very low blood glucose concentrations
50 compared to mammals, blood glucose reference values in healthy bearded dragons are higher at 153-
51 308 mg/dL (8.49-17.09 mmol/L) (Heatley and Russell, 2019; Raiti, 2019; Howard and Jaensch, 2021).

52 In addition to aiding clinical diagnoses, blood glucose concentration also informs clinical
53 decision-making. For example, accurate blood glucose concentration measurement is important for fluid
54 therapy planning and treatment response monitoring. A recent investigation demonstrated that
55 administration of 2.5% dextrose solution by either subcutaneous or intracoelomic route resulted in
56 significant increases in blood glucose concentration within 5 minutes (Minor *et al.*, 2021). In
57 experimentally dehydrated bearded dragons, administration of reptile Ringer solution (1:1 mixture of
58 5% dextrose and isotonic crystalloid solution), historically recommended over lactated Ringer solution,
59 resulted in severe hyperglycemia and electrolyte changes that persisted at least 24 hours and is
60 therefore not recommended (Parkinson and Mans, 2020). Neither lactated Ringer solution nor Plasma-
61 Lyte A administration resulted in hyperglycemia, electrolyte changes, or increased blood lactate
62 concentration (Parkinson and Mans, 2020).

63 Blood glucose concentration may also aid in determining prognosis. In chelonians as well as
64 mammals, derangements in blood glucose at the time of hospital presentation are associated with
65 increased odds of death (Harcourt-Brown and Harcourt-Brown, 2012; Colon and Di Girolamo, 2020). In
66 cold-stunned Kemp's ridley turtles (*Lepidochelys kempii*), plasma glucose concentration at initial
67 presentation was similar between survivors and nonsurvivors, but over the first 2-3 days of
68 hospitalization glucose tended to increase in survivors and decrease in nonsurvivors (Keller *et al.*, 2012).
69 While similar studies have yet to be conducted in bearded dragons, severe glucose derangements may
70 occur in critical patients, indicating a need for a more aggressive diagnostic and treatment plan.

71 Portable blood glucose meters (PBGMs) are inexpensive alternatives to traditional benchtop
72 analyzers and can be useful when limited blood volume can be collected or results are needed

73 immediately. However, prior to use in a novel species, the PBGM should be assessed for analytical and
74 clinical agreement with the reference analyzer (Gerber and Freeman, 2016). In many cases, there is
75 insufficient agreement to recommend the use of the PBGM, as unpredictable variation could cause
76 important clinical errors (Selleri *et al.*, 2014; Higbie *et al.*, 2015; Capasso *et al.*, 2019; Proulx *et al.*, 2022).
77 Poor agreement can be due to different analyzer methodologies, such as the enzymes used to react with
78 glucose or the transducers used for measurement (Gerber and Freeman, 2016). Further, some PBGMs
79 have a filter that separates the red blood cells from the plasma, while others do not and measure
80 glucose concentration from whole blood (Gerber and Freeman, 2016). Plasma glucose concentration
81 tends to be higher than whole blood glucose (Gerber and Freeman, 2016). Some PBGMs have built-in
82 algorithms designed to generate a plasma equivalent from a whole blood capillary sample for ease of
83 comparison to benchtop methods; however, these algorithms may be species-specific, taking into
84 account factors such as glucose distribution between plasma and red blood cells and may be affected by
85 hematocrit (Gerber and Freeman, 2016). Thus, agreement should be assessed for a new species, as well
86 as under a range of variables such as packed cell volumes (PCV) (Gerber and Freeman, 2016). Error
87 associated with hemodiluted or hemoconcentrated samples has been documented in species including
88 humans, dogs, cats, and rabbits (Mann *et al.*, 2008; Lane *et al.*, 2015; Lane and Koenig, 2019; Cutler *et*
89 *al.*, 2020). In rabbits, correction equations accounting for PCV resulted in improved agreement with the
90 reference method for human glucometers, but did not improve agreement for veterinary glucometers
91 (Cutler *et al.*, 2020). Thus, in some cases it is possible to determine correction equations, while in other
92 cases the PBGM simply should not be used.

93 The objective of this study was to evaluate three PBGMs for potential glucose concentration
94 measurement in inland bearded dragons. Two human devices and one veterinary device with two
95 settings (canine and feline) were assessed for agreement with a reference analyzer. Additionally, the
96 potential effects of variables including PCV, total solids (TS), lipemia, and hemolysis were evaluated.

97

98 **Material and Methods**

99 This research was approved by the University of California-Davis (UC Davis) Institutional Animal
100 Care and Use Committee (protocol #22816).

101

102 **Animals:** Forty-eight captive-born adult inland bearded dragons (23 males and 25 females) originally
103 selected for culling from a breeding facility (Chico, CA, USA) were evaluated. Culling decisions were
104 made by the breeder based on genetics, age, or unspecified health concerns. Ages ranged from 1.5-7
105 years old, and mean weight was 305 g +/- 79 g. Bearded dragons were fed a combination of crickets,
106 mealworms, and dark leafy greens supplemented with a calcium carbonate powder and provided water
107 in a bowl. Prior to sampling, animals were temporarily housed at the UC Davis – Teaching and Research
108 Animal Care Services headquarters in glass enclosures with mercury vapor bulbs and fasted for 48 hours.
109 Ambient room temperature was maintained between 26.4-30°C (79.5-86°F) during the day (05:00-
110 17:00), with individual heat lamps providing a range up to 33.3°C (91.9°F). Night temperatures were
111 26.7-28.9°C (80.1-84°F). Humidity was not monitored. Based on intake physical examination, all dragons
112 appeared alert, hemodynamically stable, euhydrated, and free from pain.

113

114 **Sample collection:** Each bearded dragon was sedated with a subcutaneous injection of alfaxalone (10
115 mg/kg, Alfaxan multidose, Jurox, Kansas City, MO, USA) in the cranial half of the body. Once sedation
116 was achieved, characterized by decreased response to external stimuli, muscle relaxation, and
117 decreased purposeful movement (Shippy *et al*, 2023), the phlebotomy site was prepped with a 70%
118 alcohol swab and allowed to dry. Up to 2.5 ml blood was collected from the caudal tail or jugular vein
119 using a 25-gauge needle and 3 mL syringe.

120

121 **Biochemical analysis:** Whole blood drops were immediately applied to three PBGMs: a veterinary PBGM
122 (VPBGM, AlphaTrak 2, Zoetis, Parsipanny, NJ, USA) set to canine (cVPBGM), a second identical VPBGM
123 (AlphaTrak 2) set to feline (fVPBGM), and a human PBGM (HPBGM, Accu-Chek® Guide, Roche Diabetes
124 Care Inc., Indianapolis, IN, USA). PBGMs were checked weekly prior to use with control solution in
125 accordance with manufacturer guidelines. The VPBGM requires 0.3 µL whole blood per test strip and
126 has a detection range of 20-750 mg/dL (1.11–41.6 mmol/L). Proprietary formulas convert the result to a
127 species-specific (canine or feline) plasma equivalent. The HPBGM requires 0.6 µL whole blood, serum, or
128 plasma per test strip, with a detection range of 10-600 mg/dL (0.555-33.3 mmol/L). The HPBGM also has
129 built-in calculations that provide the result as a human plasma equivalent. While both analyzers utilize
130 an enzymatic reaction with glucose dehydrogenase, the VPBGM measures the resultant current using
131 coulometry whereas the HPBGM uses amperometry.

132 The remaining blood was placed into 0.4 ml lithium heparin collection tubes without plasma
133 separator and 0.5 ml K₂EDTA tubes (BD microtainer, Becton Dickinson and Company, Franklin Lakes, NJ,
134 USA). Blood tubes were placed on ice until further processing for not more than 2 hours after collection.
135 PCV and TS were determined in duplicate from the K₂EDTA samples using microhematocrit tubes
136 without additive. Glucose was opportunistically measured using 40 µL heparinized whole blood with a
137 portable human analyzer (LDX, Cholestech LDX™ Analyzer, Abbott Point of Care Diagnostics, Princeton,
138 NJ, USA) as part of a lipid panel (Cholestech LDX™ Lipid Profile GLU cassette, Abbott Point of Care
139 Diagnostics) being performed for a related study (Beaufrère *et al.*, 2024). The Cholestech LDX™ Optics
140 Check Cassette (Abbott Point of Care Diagnostics) was run daily in accordance with manufacturer's
141 instructions to ensure the optical system was functioning appropriately. The LDX determines glucose
142 concentration utilizing reflectance photometry following an enzymatic reaction with glucose oxidase.

143 Remaining lithium heparin tubes were centrifuged at 3000 x g for 7 minutes. Plasma was
144 removed with plastic micropipettes and stored in 0.5 mL polypropylene tubes (Eppendorf, Hamburg,

145 Germany) at -80°C (-112°F) until analysis. Samples were collected over the course of 3 weeks, then all
146 heparinized plasma was submitted simultaneously to the University of Miami Miller School of Medicine
147 Avian and Wildlife Laboratory (Miami, FL, USA) for biochemistry panel on a reference biochemistry
148 analyzer (Vitros 5600 dry slide chemistry analyzer, Ortho Clinical Diagnostics Inc., Rochester, NY, USA)
149 which included glucose. Hemolysis was graded on a scale of 0-3+ by visual examination, with 0 indicating
150 a non-hemolytic sample (clear plasma color), and 1+, 2+, and 3+ representing mild, moderate, and
151 marked hemolysis, respectively, as previously described (Stacy *et al.*, 2019). Lipemia was similarly
152 graded visually on a 0–4 scale with 0 having no lipemia, 1 being mildly lipemic, and 4 being the most
153 severely lipemic. The reference analyzer was calibrated daily with commercial quality controls in
154 accordance with manufacturer instructions. The reference analyzer utilizes enzymatic reactions with
155 glucose oxidase and peroxidase in the presence of dye, which is measured by colorimetry.

156 To establish bearded-dragon-specific coefficients of variations (CV) for each analyzer, samples
157 from 5 bearded dragons were run in quintuplicates on the reference analyzer, HPGBM, and LDX, and
158 under both the canine and feline setting for the VPBGMs.

159
160 **Statistical Analysis:** Statistical analysis was performed using conventional units (mg/dL) to remain
161 consistent with values reported by the analyzers. The agreement between the PGBMs and the reference
162 analyzer was investigated using difference plots (Fig. 1) and Passing-Bablok regression analysis (Fig. 2).
163 For the Passing-Bablok regression analysis, the constant bias (meter – reference method) is represented
164 by the intercept of the regression line and should be different from 0 to be significant (0 not included in
165 the 95% confidence interval) whereas the proportional bias is represented by the slope of the regression
166 line and should be different from 1 to be significant (1 not included in the 95% confidence interval). For
167 the difference plot, the bias was plotted against the reference method. The 95% limits of agreement
168 (LOA) were obtained by the following formula: $\text{bias} \pm 1.96 \sqrt{\sigma^2}$ with σ^2 the variance of the bias.

169 Acceptance limits, within which the two analyzers were considered analytically identical
170 (hereafter referred to as analytical agreement), were defined as: $\text{bias} \pm 1.96 * \text{CV}$ where CV was the
171 combined coefficient of variation of both techniques [$\text{CV} = \sqrt{\text{CV}_1^2 + \text{CV}_2^2}$] (Jensen and Kjelgaard-Hansen,
172 2006). Acceptance limits represent the acceptability based on the inherent imprecision of both methods.

173 Clinical decision limits, within which discrepancies between the two analyzers would not lead to
174 alteration in clinical decisions (hereafter referred to as clinical agreement), were based on the concept of
175 total allowable errors (TE_a) and set at 20% according to published TE_a values for blood glucose in
176 mammals (Harr *et al.*, 2013). The observed total error (TE_{obs}) of the study was calculated as $2\text{CV} + \text{Bias}\%$
177 and was used to interpret clinical agreement. If TE_{obs} was lower than the acceptance limits, then
178 analytical agreement was interpreted as acceptable. If TE_{obs} was lower than the decision limits, then
179 clinical agreement was interpreted as acceptable (Harr *et al.*, 2013).

180 The clinical decision limits were also plotted on the Passing-Bablok plots. Graphically, agreement
181 was considered adequate when 95% of the datapoints were within these limits. Spearman correlation
182 coefficients were also obtained between the analyzers (weak when $\rho \leq 0.3$, moderate when $0.3 < \rho \leq 0.7$,
183 and strong when $\rho > 0.7$). Passing-Bablok regression equations were used to generate corrective
184 formulas, whenever required.

185 To investigate the potential effect of PCV, glucose, TS, lipemia, and hemolysis on the agreement,
186 the bias was modelled using a multiple linear regression model including the reference method
187 concentrations as a covariable to account for proportional bias and the type of analyzer to control for
188 analyzers. Assumptions of normality of the residuals, homoscedasticity, linearity, and the presence of
189 outliers were checked on residual and quantile plots. R Statistical Software (Version 4.2.2, R Core Team
190 2022, R foundation for statistical computing, Vienna, Austria. <http://www.R-project.org/>) was used for
191 statistical analysis. An alpha of 0.05 was used for statistical significance.

192

193 **Results**

194 One bearded dragon was excluded due to blood glucose levels above the limits of detection for
195 the HPBGM and VPBGM (1577 mg/dL [87.52 mmol/L] via reference method) thus final sample size was
196 47 bearded dragons. This severely hyperglycemic animal was later euthanized; post-mortem
197 examination revealed a gastric neuroendocrine carcinoma with hepatic metastasis. Blood glucose
198 concentration for the other 47 animals on the reference analyzer ranged from 127-419 mg/dL (7.05-23.3
199 mmol/L) with a mean of 192 mg/dL (10.7 mmol/L) and a median of 182 mg/dL (10.1 mmol/L). Three
200 samples were hypoglycemic, 13 euglycemic, and 2 hyperglycemic (Howard and Jaensch, 2021).
201 Reliability statistics are reported in Table 1.

202 Precision was generally good for all analyzers with the LDX having the lowest precision (Table 1).
203 A strong correlation was found for all PBGMs with the reference analyzer.

204 The VPBGM had significant constant and proportional biases in canine and feline modes (Fig. 1,
205 2, Table 1). Both the HPBGM and LDX only had significant proportional biases (Fig. 1, 2, Table 1). The
206 VPBGM was found to overestimate the blood glucose on both settings, while the HPBGM and LDX were
207 found to underestimate the blood glucose. These respective discrepancies became more pronounced at
208 higher blood glucose concentrations due to the significant proportional biases.

209 On the Passing-Bablok plots, only the LDX was found to be in clinical agreement with the
210 reference analyzer (Fig. 2). However, if correction formulas were applied, all analyzers were found to be
211 in clinical agreement (Fig. 2). Correction equations, as generated by Passing-Bablok regression
212 equations, were as follows:

213

214

cVPBGM

215

Reference analyzer equivalent = (cVPBGM + 54 mg/dL)/1.7

216

217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240

fVPBGM

$$\text{Reference analyzer equivalent} = (\text{fVPBGM} + 42 \text{ mg/dL})/1.5$$

HPBGM

$$\text{Reference analyzer equivalent} = (\text{HPBGM} + 0.5 \text{ mg/dL})/0.8$$

LDX

$$\text{Reference analyzer equivalent} = (\text{LDX} - 9 \text{ mg/dL})/0.9$$

No analyzers had TE_{obs} within the analytical acceptance limits. Only the LDX had TE_{obs} within the clinical decision limits. The corrective formula obtained from the Passing-Bablok regression analysis was applied to the PBGM values and the bias recalculated to generate corrected LOA and TE_{obs} (Table 2). When corrective formulas were applied, all analyzers were within clinical decision limits.

A higher PCV was overall associated with an increasingly negative constant bias (-1.03 ± 0.41 mg/dL per PCV unit, $P < 0.004$) controlling for glucometers. There was no effect of TS ($P = 0.22$) and lipemia ($P = 0.23$). No samples had hemolysis and nine samples were lipemic.

Discussion

All PBGMs lacked analytical agreement with the reference analyzer and thus cannot be used interchangeably. Only the LDX demonstrated clinical agreement with the reference analyzer, which may be in part because the LDX utilizes the same glucose oxidase enzymatic reaction as the reference analyzer. Passing-Bablok regression analysis showed proportional bias was of greatest magnitude with the VPBGM. Negative proportional bias was present for the LDX and HPBGM, resulting in a tendency to underestimate blood glucose concentration. Proportional bias was positive for the VPBGM on both

241 settings, resulting in overestimation of blood glucose concentration within the range of values
242 evaluated. However, for both settings on the VPBGM, due to the concurrent presence of negative
243 constant bias, concentrations could be underestimated with severe hypoglycemia (*e.g.*, <77 mg/dL [4.27
244 mmol/L] on reference method; concentrations this low were not assessed in the data set).

245 A similar recently discontinued HPBGM (Accu-Chek® Aviva, Roche Diabetes Care Inc.,
246 Indianapolis, IN, USA) has been evaluated in rabbits and ferrets, with both tending to underestimate as
247 in bearded dragons (Petritz *et al.*, 2013; Selleri *et al.*, 2014). Similar to bearded dragons, the TE_{obs} in
248 rabbits for the HPBGM was unacceptable but lower compared to the VPBGM (Selleri *et al.*, 2014).

249 VPBGM trends were similar to those found for the same analyzer in dogs and rabbits, but not
250 ferrets (Selleri *et al.*, 2014; Proulx *et al.*, 2022; Wolfenden *et al.*, 2022). As in bearded dragons, the
251 VPBGM tended to overestimate blood glucose concentration in rabbits on both the feline and canine
252 setting, and in dogs on the canine setting (Selleri *et al.*, 2014; Wolfenden *et al.*, 2022). In rabbits, due to
253 positive proportional bias, overestimation increased on both settings at higher blood glucose
254 concentrations as in bearded dragons (Selleri *et al.*, 2014). In ferrets, this VPBGM was overall
255 unpredictable but more commonly underestimated blood glucose concentration (Proulx *et al.*, 2022).

256 Similar to rabbits, a negative bias was of greater magnitude at higher PCVs for all PBGMs tested
257 in this study (Cutler *et al.*, 2020). Correction equations for PCV have been experimentally derived
258 successfully in rabbits for a HPBGM (Accu-Chek® Aviva), but did not improve agreement when applied to
259 the VPBGM (Cutler *et al.*, 2020). While insufficient PCV range was present in this data set to derive PCV
260 correction equations, future studies could assess PCV corrections in bearded dragons using
261 experimentally diluted blood samples (Cutler *et al.*, 2020).

262 These results demonstrate that trends are not consistent across species, especially for the
263 VPBGM, and should not be extrapolated in the absence of quality assurance data. Additionally, trends
264 may not be conserved even within the same manufacturer and evaluation of new models is necessary.

265 Recent evaluation of the VPBGM in ferrets gave different results from a study with the original
266 discontinued model (Alpha Trak, Abbott Laboratories, Abbott Park, IL, USA), indicating evaluation of new
267 models is necessary (Petritz *et al.*, 2013; Proulx *et al.*, 2022). Differing trends are likely multifactorial and
268 associated with variables such as analyzer methodology, inherent algorithms intended to provide a
269 plasma equivalent, species-specific glucose distribution between erythrocytes and plasma, and
270 hematocrit (Gerber and Freeman, 2016).

271 While the VPBGM and HPBGM are inexpensive analyzers compared to the LDX and reference
272 analyzer, additional steps such as application of corrective formulas are necessary to ensure acceptable
273 diagnostic results. Alternatively, as precision was good for all analyzers and correlation to the reference
274 analyzer was strong, method-specific reference intervals could be generated (Friedrichs *et al.*, 2012).
275 Should reference intervals be made for a PBGM, we suggest use of the HPBGM due to cost of the LDX
276 compared to the other analyzers, and greater magnitude of bias with the VPBGM. A new VPBGM model
277 by the same manufacturer was recently released, but resources may be better directed towards a
278 HPBGM.

279 Precision was lowest for the LDX; pre-analytical error such as presence of air bubbles may have
280 been present during the replication study. Potential sources of preanalytical error were otherwise
281 minimal. Based on chelonian studies, refrigerated heparinized reptilian blood samples have minimal
282 changes in glucose and hemolysis during the first 24 hours even if plasma is in contact with cells (Heatley
283 and Russell, 2019). In future studies, an alternative buffer such as citrate could be considered to improve
284 blood glucose stability (Lippi *et al.*, 2018). For the reference method biochemistry panel, all samples
285 were shipped on the same day, resulting in lack of standard interval between collection and
286 measurement (range 1-21 days). However, samples were kept at -80°C prior to and during shipping;
287 glucose has been shown to be stable in lithium heparinized plasma samples when frozen for up to 12
288 weeks, with no significant difference in bias between 2 and 4 weeks of storage (Pleus *et al.*, 2022).

289 Human medicine utilizes Clarke error grid analysis, which categorizes clinical PBGM accuracy on
290 the basis of therapeutic consequences (Proulx *et al.*, 2022). For example, region A indicates the 20% TE_a
291 where 95% of the results should fall, and region E indicates the most dangerous scenarios, such as
292 where erroneous reading of hyperglycemia might result in insulin administration (Proulx *et al.*, 2022). At
293 this time specific criteria for treating hypo- or hyperglycemia in bearded dragons has not been
294 determined however error grid analysis could be considered in future studies.

295 Additional point of care analyzers designed for use in reptiles are available, such as the Abaxis
296 Vetscan VS2 (Zoetis, Parsipanny, NJ, USA). Studies in other reptile species such as Hermann's tortoises
297 (*Testudo hermanni*) have found the Abaxis Vetscan VS2 to overestimate glucose concentrations (Di
298 Girolamo *et al.*, 2018). While assessment of the Abaxis Vetscan VS2 was cost-prohibitive for this study,
299 evaluation could be considered in the future. The Vetscan uses a hexokinase-based reaction to measure
300 glucose, which was not utilized by any of the analyzers in the present study and may be worth
301 investigating (Di Girolamo *et al.*, 2018).

302 Several recent studies have evaluated the effects of alfaxalone in bearded dragons (Perrin and
303 Bertelsen, 2017; Shippy *et al.*, 2023; Webb *et al.*, 2023). In one study, intravenous alfaxalone at 12
304 mg/kg resulted in rapid anesthetic induction, subsequent intubation, and a surgical plane of anesthesia,
305 with apnea occurring in 25% of dragons (Perrin and Bertelsen, 2017). In another, 15 mg/kg alfaxalone
306 did not cause apnea regardless of route (intracoelomic, subcutaneous, intramuscular, or intravenous)
307 (Webb *et al.*, 2023). While intravenous administration provided the most consistent sedation, no
308 significant differences were found between administration routes for time to loss and recovery of
309 responses and reflexes (Webb *et al.*, 2023). In our study, a lower dose of 10 mg/kg was utilized in an
310 effort to avoid apnea and because a surgical plane was not required. Subcutaneous administration was
311 elected due to large injection volume. Alfaxalone was administered in the cranial half of the body in our
312 study to avoid the renal portal system and liver shunting, as deeper anesthesia is achieved in ball

313 pythons when alfaxalone is administered cranially instead of caudally (James *et al.*, 2018). However, a
314 recent publication in bearded dragons found no significant differences in plasma concentrations, time to
315 loss of righting reflex, or time to recovery of righting reflex when 10 mg/kg alfaxalone was administered
316 intramuscularly in either the cranial or caudal half of the body (Shippy *et al.*, 2023).

317 This study confirms the need for assessment of PBGM agreement prior to adoption in a new
318 species, and that trends may not be conserved across species. Use of a VPBGM or HPBGM can be
319 considered in bearded dragons provided correction equations are applied, or analyzer-specific reference
320 intervals are determined.

321

322

323 **Acknowledgements:** This study was funded by the UC Davis Sue Solomon Reptile Research Fund and the
324 Students Training in Advanced Research (STAR) program, University of California-Davis; School of
325 Veterinary Medicine.

326

327 **Disclaimer:** The authors have no conflict of interests to declare.

328

329

330 **Literature Cited**

331 Anderson KB, Meinkoth J, Hallman M, Bailey K, Brandão J. 2019. Cytological diagnosis of gastric
332 neuroendocrine carcinoma in a pet inland bearded dragon (*Pogona vitticeps*). J Exot Pet Med, 29:
333 188–193.

334 Beaufrère H, Pacumio L, Susta L, Tarbert DK, Ammersbach M, Keel K. 2024. Hepatic lipid accumulation is
335 associated with multiple metabolic pathway alterations but not dyslipidemia and insulin
336 resistance in central bearded dragons (*Pogona vitticeps*). Am J Vet Res, 85(6):1-10.

337 Capasso M, Di Girolamo N, Silvestre P, Laricchiuta P. 2019. Performance of two portable blood glucose
338 meters for measuring blood glucose concentration in tigers (*Panthera tigris*) and lions (*Panthera*
339 *leo*). J Am Vet Med Assoc, 254(3):399-408.

340 Colon VA, Di Girolamo N. 2020. Prognostic value of packed cell volume and blood glucose concentration
341 in 954 client-owned chelonians. J Am Vet Med Assoc, 257(12):1265–1272.

342 Cutler DC, Koenig A, Di Girolamo N, Mayer J. 2020. Investigation for correction formulas on the basis of
343 packed cell volume for blood glucose concentration measurements obtained with portable
344 glucometers when used in rabbits. Am J Vet Res, 81(8):642–650.

345 Di Girolamo N, Ferlizza E, Selleri P, Nardini G, Isani G. 2018. Evaluation of point-of-care analysers for
346 blood gas and clinical chemistry in Hermann’s tortoises (*Testudo hermanni*). J Small Anim Pract,
347 59(11):704–713.

348 Friedrichs KR, Harr KE, Freeman KP, Szladovits B, Walton RM, Barnhart KF, Blanco-Chavez J. 2012. ASVCP
349 reference interval guidelines: determination of de novo reference intervals in veterinary species
350 and other related topics. Vet Clin Pathol, 41(4):441-453.

351 Frye F. 1991. Biomedical and Surgical Aspects of Captive Reptile Husbandry, 2nd ed. Krieger Publishing,
352 Malabar, FL, USA.

353 Gerber KL, Freeman KP. 2016. ASVCP guidelines: Quality assurance for portable blood glucose meter
354 (glucometer) use in veterinary medicine. Vet Clin Pathol, 45(1):10–27.

355 Harcourt-Brown FM, Harcourt-Brown S. 2012. Clinical value of blood glucose measurement in pet
356 rabbits. Vet Rec, 170(26):674.

357 Harr KE, Flatland B, Nabity M, Freeman KP. 2013. ASVCP guidelines: allowable total error guidelines for
358 biochemistry. Vet Clin Pathol, 42(4):424–436.

359 Heatley JJ, Russell KE. 2019. Clinical chemistry. In Divers SJ, Stahl SJ (eds.): Mader’s Reptile and
360 Amphibian Medicine and Surgery. Elsevier, St. Louis, MO, USA:319–332.

361 Hepps Keeney CM, Intile JL, Sims CS, Harrison TM. 2021. Lymphoid leukemia in five bearded dragons
362 (*Pogona vitticeps*). J Am Vet Med Assoc, 258(7):748–757.

363 Higbie CT, Eshar D, Bello NM. 2015. Evaluation of three point-of-care meters and a portable veterinary
364 chemistry analyzer for measurement of blood glucose concentrations in black-tailed prairie dogs
365 (*Cynomys ludovicianus*). Am J Vet Res, 76(6):532–539.

366 Howard JG, Jaensch S. 2021. Haematology and plasma biochemistry reference intervals in wild bearded
367 dragons (*Pogona vitticeps*). Aust Vet J, 99(6):236–241.

368 James LE, Williams CJ, Bertelsen MF, Wang T. 2018. Anaesthetic induction with alfaxalone in the ball
369 python (*Python regius*): Dose response and effect of injection site. Vet Anaesth Analg, 45(3):329-
370 337.

371 Jensen AL, Kjelgaard-Hansen M. 2006. Method comparison in the clinical laboratory. Vet Clin Pathol,
372 35(3):276–286.

373 Keller KA, Innis CJ, Tlusty MF, Kennedy AE, Bean SB, Cavin JM, Merigo C. 2012. Metabolic and respiratory
374 derangements associated with death in cold-stunned Kemp’s ridley turtles (*Lepidochelys kempii*):
375 32 cases (2005–2009). J Am Vet Med Assoc, 240(3):317–323.

376 Lane SL, Koenig A. 2019. Development and evaluation of a formula to correct blood glucose
377 concentration measurements in hemodiluted and hemoconcentrated feline blood samples tested
378 by use of a veterinary point-of-care glucometer. J Am Vet Med Assoc 254(10):1180–1185.

379 Lane SL, Koenig A, Brainard BM. 2015. Formulation and validation of a predictive model to correct blood
380 glucose concentrations obtained with a veterinary point-of-care glucometer in hemodiluted and
381 hemoconcentrated canine blood samples. J Am Vet Med Assoc, 246(3):307–312.

382 Lippi G, Nybo M, Cadamuro J, Guimaraes JT, van Dongen-Lases E, Simundic AM. 2018. Blood glucose
383 determination: Effect of tube additives. Adv Clin Chem, 84:101–123.

384 Mann EA, Salinas J, Pidcoke HF, Wolf SE, Holcomb JB, Wade CE. 2008. Error rates resulting from anemia
385 can be corrected in multiple commonly used point-of-care glucometers. *J Trauma*, 64(1):15–20.

386 Minor RL, Doss GA, Mans C. 2021. Evaluation of glucose absorption rates following intracoelomic or
387 subcutaneous administration in experimentally dehydrated inland bearded dragons (*Pogona*
388 *vitticeps*). *Am J Vet Res*, 82(11):920–923.

389 Parkinson LA, Mans C. 2020. Evaluation of subcutaneously administered electrolyte solutions in
390 experimentally dehydrated inland bearded dragons (*Pogona vitticeps*). *Am J Vet Res*, 81(5):437–
391 441.

392 Perrin KL, Bertelsen MF. 2017. Intravenous alfaxalone and propofol anesthesia in the bearded dragon
393 (*Pogona vitticeps*). *J Herp Med Surg*, 27(3), 123-126.

394 Petritz OA, Antinoff N, Chen S, Kass PH, Paul-Murphy JR. 2013. Evaluation of portable blood glucose
395 meters for measurement of blood glucose concentration in ferrets (*Mustela putorius furo*). *J Am*
396 *Vet Med Assoc*, 242(3):350–354.

397 Pleus S, Freckmann G, Baumstark A, Haug C. 2022. Stability of glucose concentrations in frozen plasma. *J*
398 *Diabetes Sci Technol*, 16(5):1096–1100.

399 Proulx MP, Vergneau-Grosset C, Ebert JH, Edard CB, Maccolini E. 2022. Comparison of a portable blood
400 glucose meter analyzer with a benchtop point-of-care chemistry analyzer for measurement of
401 blood glucose concentration in client-owned ferrets (*Mustela putorius furo*). *J Exot Pet Med*,
402 43:22–28.

403 Raiti P. 2019. Endocrinology. *In* Divers SJ, Stahl SJ (eds.): *Mader’s Reptile and Amphibian Medicine and*
404 *Surgery*. Elsevier, St. Louis, MO, USA:835-848.

405 Ritter JM, Garner MM, Chilton JA, Jacobson ER, Kiupel M. 2009. Gastric neuroendocrine carcinomas in
406 bearded dragons (*Pogona vitticeps*). *Vet Path*, 46(6):1109-1116.

407 Selleri P, Di Girolamo N, Novari G. 2014. Performance of two portable meters and a benchtop analyzer
408 for blood glucose concentration measurement in rabbits. *J Am Vet Med Assoc*, 245(1):87–98.

409 Shippy S, Allgood H, Messenger K, Hernandez JA, Gatson B, Martin de Bustamante MG, Alexander AB,
410 Wellehan JF, Johnson A. 2023. Pharmacokinetics and pharmacodynamics of intramuscular
411 alfaxalone in central bearded dragons (*Pogona vitticeps*): Effect of injection site. *Vet Anaesth*
412 *Analg* 50(3):280–288.

413 Stacy NI, Chabot RM, Innis CJ, Cray C, Fraser KM, Rigano KS, Perrault JR. 2019. Plasma chemistry in
414 nesting leatherback sea turtles (*Dermochelys coriacea*) from Florida: Understanding the
415 importance of sample hemolysis effects on blood analytes. *PLoS One*, 14(9):e0222426.

416 Webb JK, Keller KA, Chinnadurai SK, Kadotani S, Allender MC, Fries R. 2023. Use of alfaxalone in bearded
417 dragons (*Pogona vitticeps*): Optimizing pharmacodynamics and evaluating cardiogenic effects via
418 echocardiography. *J Am Vet Med Assoc*, 261(1):126–131.

419 Wolfenden G, James FE, Hung LHT, Bruce M, Thompson M. 2022. Comparative accuracy of two
420 veterinary-calibrated point-of-care glucometers for measurement of blood glucose concentration
421 in dogs. *J Small Anim Pract*, 63(7):512–519.

422

423 **Table 1:** Results from methods comparison analysis evaluating analytical and clinical agreement of three
 424 portable glucose meters (PBGMs) with a reference analyzer in inland bearded dragons (*Pogona*
 425 *vitticeps*). PBGMs assessed included a veterinary PBGM (VPBGM) using the canine and feline settings, a
 426 human PBGM (HPBGM), and a human point-of-care analyzer (LDX). Passing-Bablok regression analysis
 427 was used to identify constant and proportional bias. Difference plots were used to determine bias based
 428 on mean differences and calculate 95% limits of agreement (LOA). Observed total error (TE_{obs}) was
 429 calculated using bearded dragon-specific coefficients of variation (CV) for each analyzer and bias as
 430 determined by the difference plots. Acceptance limits (analytical agreement) were calculated using the
 431 combined CV of both analyzers. Clinical decision limits (clinical agreement) were based on mammalian
 432 total allowable error (TE_a) guidelines. No analyzers had TE_{obs} within the analytical acceptance limits and
 433 only the LDX had TE_{obs} within the clinical decision limits. CI = confidence interval.

	N	CV	ρ	Constant	Proportional	LOA	TEobs	Acceptance	Clinical
		(%)		bias (95%	bias (95%	(mg/dL)	(%)	limits (%)	decision
				CI ;	CI ; mg/dL)				limits
				mg/dL)					(%)
cVPBGM	47	2.1	0.90	-54 (-114;	1.7	54.4	42.8	4.2	20
(AlphaTrak				-7)*	(1.4;2.0)*				
2,									
canine									
setting)									
fVPBGM	47	2.6	0.85	-42 (-	1.5	55.0	31.0	5.2	20
(AlphaTrak				105;-5)*	(1.2;1.8)*				
feline									
setting)									

HPBGM	47	1.5	0.90	-0.5 (-	0.8	31.0	24.1	3.0	20
(Accu- Chek® Guide)				29.1;18.5)	(0.7;0.9)*				
LDX	38	5.0	0.92	9 (-6;24)	0.9	38.5	16.3	9.8	20
(Cholestech LDX™ Analyzer)					(0.8;0.98)*				
Reference method	47	0.4	NA	NA	NA	NA	NA	NA	NA

434

435

436 **Table 2:** Results following application of corrective formulas to methods comparison analysis evaluating
 437 analytical and clinical agreement of three portable glucose meters (PBGMs) with a reference analyzer in
 438 inland bearded dragons (*Pogona vitticeps*). PBGMs assessed included a veterinary PBGM (VPBGM) using
 439 the canine and feline settings, a human PBGM (HPBGM), and a human point-of-care analyzer (LDX). The
 440 corrective formulas were obtained from Passing-Bablok regression analysis and applied to the PBGM
 441 values. Bias was recalculated to generate corrected 95% limits of agreement (LOA) and observed total
 442 error (TE_{obs}). When corrective formulas were applied, all analyzers were within the 20% total allowable
 443 error (TE_a) clinical decision limit.

444

	LOA	TEobs
	corrected	corrected
	(mg/dL)	(%)
cVPBGM	29.0	13.9
(AlphaTrak 2, canine setting)		
fVPBGM	40.4	11.0
(AlphaTrak 2, feline setting)		
HPBGM (Accu- Chek® Guide)	25.3	4.2
LDX (Cholestech LDX™ Analyzer)	39.1	10.4

445

446 **Figure Legends**

447

448 **Figure 1:** Difference plot of the bias on y-axis against the reference method concentrations of blood
449 glucose for portable blood glucose meters (PBGMs) in inland bearded dragons (*Pogona vitticeps*). The
450 plain line represents the line of perfect agreement, the dotted line represents the mean bias and the
451 dashed lines present the 95% limits of agreement. Upward trends seen with increasing glucose values
452 are compatible with a positive proportional bias (VPBGM [AlphaTrak 2]). Downward trends seen with
453 increasing glucose values are compatible with a negative proportional bias (HPBGM [Accu-Chek® Guide];
454 LDX). A) cVPBGM, AlphaTrak 2, canine setting; B) fVPBGM, AlphaTrak 2, feline setting; C) HPBGM, Accu-
455 Chek® Guide; D) LDX, Cholestech LDX™ Analyzer. POC = point of care analyzer

456

457 **Figure 2:** Plot of the glucose concentrations obtained by portable blood glucose meters (PBGMs) and a
458 reference analyzer in inland bearded dragons (*Pogona vitticeps*). The dashed line represents the line of
459 perfect agreement, the dotted line is the Passing-Bablok regression line, the grey shaded area
460 represents the clinical decision limits based on total allowable error limits centered around the Passing-
461 Bablok regression line. If the line of perfect agreement is not within the clinical decision limits, a
462 correction formula is necessary. If correction formulas are applied, the two analyzers are within clinical
463 agreement with 95% of the datapoints within the clinical decision limits.

464



